The Desmoid Tumor Research Foundation

November 2017

Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis

Author Information

Liu X(1)(2), Wang H(1)(2), Wu X(1)(2), Hong X(1)(2), Luo Z(3)(4)

(1)Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.(2)Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.(3)Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.(4)Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

Publication

Invest New Drugs

Summary

To evaluate the efficacy and safety of doxorubicin (ADM) combined with thalidomide (THA) as a first-line treatment for patients with refractory aggressive fibromatosis (AF). No patient had a complete response, but five patients had partial responses, resulting in a RR of 33%. Eight patients (53%) had stable disease and two patients (13%) had progressive disease, and the disease control rate was 87%. ADM plus THA was well-tolerated and effective as a first-line treatment for patients with refractory AF. However, patients with hypoalbuminemia at baseline had inferior clinical outcomes, and further studies are needed to investigate this issue.

View Abstract